Pharmaceuticals
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients
SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that as ofMarch 29, 2023, the company has conducted 13 clinical studies cover...
2023-03-30 08:00
4344
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
- ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn's disease - LOS ANGELES, March 30, 2023 /PRNewswire/ -- Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology ...
2023-03-30 03:32
3866
bitBiome and Kaken Pharmaceuticals sign joint research agreement on the discovery of drugs for infectious diseases
-The joint research will use bitBiome's drug discovery platform technology to search for drug candidate substances- TOKYO, March 29, 2023 /PRNewswire/ -- bitBiome, Inc. (Head office: Shinjuku-ku,Tokyo; President: Yuji Suzuki; hereafter 'bitBiome') and Kaken Pharmaceuticals (Head office: Bunkyo-k...
2023-03-29 22:00
2698
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
* Su-jin Park joins HanAll Biopharma in a shared leadership role to strengthen pharmaceutical business in Korea, supporting growth in domestic drug sales * Sean Jeong, who has been serving as Co-CEO since March 2021, will continue to lead HanAll's R&D, including its subsidiary HanAll Pharmace...
2023-03-29 19:00
2265
BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia
BRATISLAVA, Slovakia, March 29, 2023 /PRNewswire/ -- BGI Genomics is pleased to announce the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya. Zentya is a Slovak-based company that is passionate about providing patients with the latest technology in genetic screenin...
2023-03-29 16:00
2171
Fosun Pharma Announces its 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public
SHANGHAI, March 29, 2023 /PRNewswire/ -- On March 27, 2023, the release date of its 2022 Annual Report, Fosun Pharma (stock code: 600196.SH; 02196.HK) also released the2022 Corporate Social Responsibility Report, its 15th CSR report since the first which was issued in 2009. As before, Fosun Pharm...
2023-03-29 14:06
2725
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer
SUZHOU, China, March 29, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that the U.S. Food an...
2023-03-29 14:00
4327
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
* Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. * The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in p...
2023-03-29 08:30
3554
Innovent Announces 2022 Annual Results and Business Updates
Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capability ROCKVILLE, Md. and SUZHOU, China, March 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commer...
2023-03-29 08:00
6243
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
SUZHOU, China, March 28, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for...
2023-03-28 21:41
2505
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation
SHANGHAI and HONG KONG, March 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its full-year 2022 financial results and provided updates on key events and achievements since the start of 2022. 1. Sales Revenue Reached 5.6 Times Year-Over-Year ...
2023-03-28 21:40
3518
PharmaBlock Receives 2023 ACS CMO Excellence in Green Chemistry Award
NANJING, China, March 28, 2023 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CDMO company focusing on innovative chemistry and low-carbon manufacturing, announced today that it has been selected asthe winner of the 2023 CMO Excellence in Green Chemistry Award ...
2023-03-28 20:00
3211
Sirnaomics Announces 2022 Annual Results
Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights * Clinical development * STP705 - The part-one Phase IIb interim data on STP705 for the treatment of isSCC was announced, with th...
2023-03-28 19:26
8519
Seegene declares to share Syndromic PCR technologies to prevent future pandemics
* Localization of Seegene Syndromic PCR technologies with global partners for versatile and proactive response to local emerging healthcare demands. * Formation of a collaborative global network to aggressively develop innovative syndromic PCR assays, challenging boundaries of PCR application....
2023-03-28 19:00
2903
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
First-in-Class ERAP1 Inhibitor Enters Clinical Development Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) OXFORD, UK and MELBOURNE, AUSTRALIA, March 28, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on...
2023-03-28 19:00
2299
OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab
SHENZHEN, China, March 28, 2023 /PRNewswire/ -- OncoVent Co., Ltd. ("OncoVent"), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company"), yesterday entered into a license agreement with Orient EuroPharma Co., Ltd. ("OEP"). According to the terms of th...
2023-03-28 15:36
2373
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
SINGAPORE, March 28, 2023 /PRNewswire/ -- Becton Dickinson Holdings Pte Ltd (BD), a global leader in life science technologies, and the Agency for Science, Technology and Research (A*STAR),Singapore's lead public sector R&D agency, have announced an extended research partnership that will focus o...
2023-03-28 14:12
2912
Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
Tavneos® newly introduced in the 2022 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV) Recommendations recognize Tavneos®' ability to induce and sustain remission, lower glucocorticoids-induced toxic effects and pot...
2023-03-28 13:00
3304
Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors
ALAMEDA, Calif. and TAIPEI, March 27, 2023 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) technology to address gaps in cancer care, today announced the upcoming poster presentation of new ...
2023-03-28 10:00
2258
HaemaLogiX to present final data from anti-KMA CAR-T preclinical studies at AACR
SYDNEY, March 28, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech company developing novel immunotherapies for multiple myeloma, today announced that its anti-KMA CAR-T cell preclinical development has been completed and is the subject of an abstract accepted for poster presentation...
2023-03-28 09:43
2887
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
47318
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
22834
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
19772
